HK1223112A1 - Anti-tnf-alpha/cxcl10 double-targeting antibody and use thereof - Google Patents

Anti-tnf-alpha/cxcl10 double-targeting antibody and use thereof Download PDF

Info

Publication number
HK1223112A1
HK1223112A1 HK16111369.2A HK16111369A HK1223112A1 HK 1223112 A1 HK1223112 A1 HK 1223112A1 HK 16111369 A HK16111369 A HK 16111369A HK 1223112 A1 HK1223112 A1 HK 1223112A1
Authority
HK
Hong Kong
Prior art keywords
antibody
seq
amino acids
tnf
cxcl10
Prior art date
Application number
HK16111369.2A
Other languages
English (en)
Chinese (zh)
Inventor
Heun-Soo Kang
So-Hyun Park
Yeong Wook Song
Ki Chul Shin
Eun Young Lee
Eun Bong Lee
Young Woo Park
Bum-Chan PARK
Dong Hee Lee
Dong Jin Kim
Seon Ha YUN
Ke Se LEE
Hyun Ju Lee
Kyung Jin Kim
Hee Chan Kim
Seok Ho Yoo
Myeoung Hee Jang
Seil Jang
Original Assignee
Metabolic Engineering Laboratories Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Metabolic Engineering Laboratories Co., Ltd. filed Critical Metabolic Engineering Laboratories Co., Ltd.
Publication of HK1223112A1 publication Critical patent/HK1223112A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Toxicology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Otolaryngology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
HK16111369.2A 2013-05-22 2014-05-22 Anti-tnf-alpha/cxcl10 double-targeting antibody and use thereof HK1223112A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
KR20130057475 2013-05-22
KR20130057762 2013-05-22
KR20130057762 2013-05-22
KR20130057475 2013-05-22
PCT/KR2014/004579 WO2014189306A1 (ko) 2013-05-22 2014-05-22 항 ＴＮＦ-α/ＣＸＣＬ10 이중 타겟 항체 및 그의 용도

Publications (1)

Publication Number Publication Date
HK1223112A1 true HK1223112A1 (en) 2017-07-21

Family

ID=51933801

Family Applications (1)

Application Number Title Priority Date Filing Date
HK16111369.2A HK1223112A1 (en) 2013-05-22 2014-05-22 Anti-tnf-alpha/cxcl10 double-targeting antibody and use thereof

Country Status (11)

Country Link
US (1) US10087248B2 (cg-RX-API-DMAC10.html)
EP (1) EP3000827B1 (cg-RX-API-DMAC10.html)
JP (1) JP2016520595A (cg-RX-API-DMAC10.html)
KR (1) KR101671955B1 (cg-RX-API-DMAC10.html)
CN (1) CN105263964A (cg-RX-API-DMAC10.html)
AU (1) AU2014269287B2 (cg-RX-API-DMAC10.html)
BR (1) BR112015029224A2 (cg-RX-API-DMAC10.html)
CA (1) CA2913118A1 (cg-RX-API-DMAC10.html)
HK (1) HK1223112A1 (cg-RX-API-DMAC10.html)
PH (1) PH12015502601A1 (cg-RX-API-DMAC10.html)
WO (1) WO2014189306A1 (cg-RX-API-DMAC10.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102379464B1 (ko) 2016-06-20 2022-03-29 키맵 리미티드 항-pd-l1 항체
EP3630836A1 (en) * 2017-05-31 2020-04-08 Elstar Therapeutics, Inc. Multispecific molecules that bind to myeloproliferative leukemia (mpl) protein and uses thereof
US10654944B2 (en) 2018-04-10 2020-05-19 Y-Biologics Inc. Cell engaging binding molecules
WO2019197979A1 (en) * 2018-04-10 2019-10-17 Y-Biologics Inc. Cell engaging binding molecules
KR102088789B1 (ko) * 2018-06-20 2020-03-13 인하대학교 산학협력단 항 TNF/IFN scFv-Fc 이중 표적 항체 및 이의 이용
KR102323342B1 (ko) 2019-04-26 2021-11-08 주식회사 와이바이오로직스 IL-17A 및 TNF-α에 특이적으로 결합하는 이중표적 항체
KR102385046B1 (ko) 2020-08-24 2022-04-13 에스큐엔지니어링(주) 드론에 탈부착 점검장치를 이용한 다목적 구조물 검사장치
CA3215864A1 (en) * 2021-03-31 2022-10-06 The Regents Of The University Of California Bispecific binding agent-ligand fusions for the degradation of target proteins
KR102357756B1 (ko) 2021-05-14 2022-02-09 유한회사 서해항공방제 드론을 이용한 유해 조수 및 곤충 방제장치 및 그를 구비하는 드론
CN114432502B (zh) * 2021-12-31 2023-02-03 中山大学附属第八医院（深圳福田） 一种负载op3-4多肽、抗cxcl9抗体的水凝胶及其制备方法与应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE239041T1 (de) * 1996-02-09 2003-05-15 Basf Ag Humane antikörper welche an humanen tnfalpha binden
US20050053600A1 (en) * 2003-09-09 2005-03-10 Lane Thomas E. Methods for treating rheumatoid arthritis
WO2006102395A2 (en) * 2005-03-22 2006-09-28 Medstar Health Inc Delivery systems and methods for diagnosing and treating cardiovascular diseases
JP5757495B2 (ja) * 2005-05-16 2015-07-29 アッヴィ バイオテクノロジー リミテッド びらん性多発性関節炎の治療のためのｔｎｆ阻害剤の使用
CA2606084A1 (en) * 2005-06-17 2006-12-28 Abbott Laboratories Improved method of treating degenerative spinal disorders
JP2012228248A (ja) * 2005-08-19 2012-11-22 Abbott Lab 二重可変ドメイン免疫グロブリン及びその使用
KR20140053410A (ko) * 2005-08-19 2014-05-07 아보트 러보러터리즈 이원 가변 도메인 면역글로불린 및 이의 용도
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
TW200944231A (en) * 2007-11-30 2009-11-01 Glaxo Group Ltd Antigen-binding constructs
US20130089554A1 (en) * 2009-12-29 2013-04-11 Emergent Product Development Seattle, Llc RON Binding Constructs and Methods of Use Thereof
SI2766397T1 (sl) * 2011-10-11 2018-09-28 F. Hoffmann-La Roche Ag Izboljšano sestavljanje bispecifičnih protiteles
KR20130121601A (ko) * 2012-04-27 2013-11-06 주식회사에이앤알쎄라퓨틱스 인간 항 ｃｘｃｌ－１０ 항체 및 이를 포함하는 류마티스 관절염 치료용 조성물

Also Published As

Publication number Publication date
PH12015502601A1 (en) 2016-02-29
CN105263964A (zh) 2016-01-20
CA2913118A1 (en) 2014-11-27
AU2014269287A1 (en) 2015-12-10
EP3000827B1 (en) 2020-04-22
BR112015029224A2 (pt) 2017-09-19
US10087248B2 (en) 2018-10-02
WO2014189306A1 (ko) 2014-11-27
KR101671955B1 (ko) 2016-11-07
KR20150010919A (ko) 2015-01-29
EP3000827A1 (en) 2016-03-30
US20160108118A1 (en) 2016-04-21
WO2014189306A8 (ko) 2015-12-03
JP2016520595A (ja) 2016-07-14
AU2014269287B2 (en) 2016-08-25
EP3000827A4 (en) 2016-08-24

Similar Documents

Publication Publication Date Title
EP3000827B1 (en) Anti-tnf-alpha/cxcl10 double-targeting antibody and use thereof
JP6883591B2 (ja) 抗ヒトインターロイキン−１７ａモノクローナル抗体、その製造方法及び使用
RU2509777C2 (ru) Анти-mif антитела
CN117098561A (zh) Ccr8抗体及其应用
JP5289285B2 (ja) Ｖｅｇｆ−特異的なヒト抗体
JP2021502407A (ja) ４−１ｂｂ抗体およびその製造方法と使用
TW202613177A (zh) Gipr抗體及其與glp-1的融合蛋白質，以及其藥物組合物和應用
CN109776677B (zh) 一种人源化抗il-13抗体及其制备方法和应用
WO2017198148A1 (zh) 一种il-13抗体及其制备方法和应用
WO2021023274A1 (zh) 人源化抗TNFα抗体及其用途
CN111065651B (zh) Il-5抗体、其抗原结合片段及医药用途
WO2015113494A1 (zh) 双功能融合蛋白及其制备方法和用途
EP3178931B1 (en) Anti-orai1 antibody
KR102800024B1 (ko) 항-ｍｙｌ9 항체
US12139530B2 (en) Bispecific antibody specifically binding to IL-17A and TNF-α
CN115505041B (zh) 抗EphA2抗体及其应用
WO2025223473A1 (zh) 抗gdf-15抗体及其应用
WO2026085874A1 (zh) Tl1a结合分子及其应用
CN121930341A (zh) Tl1a结合分子及其应用
WO2026017189A2 (zh) 抗il-31抗体、其药物组合物及用途
HK40120033A (zh) 一种结合il-11的抗体、其抗原结合片段及应用
HK40120033B (en) Antibody binding to il-11, antigen-binding fragment thereof, and applications thereof
WO2025103260A9 (zh) Gdf15中和抗体及其用途
CN115572330A (zh) 一种特异性抗体及其制备方法和应用
WO2025140619A1 (zh) 包含ccr8抗原结合结构域的多特异性抗体